


## Mupirocin lithium

<b>Cat. No.:</b>	HY-W108875
<b>CAS No.:</b>	73346-79-9
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>43</sub> LiO <sub>9</sub>
<b>Molecular Weight:</b>	506.56
<b>Target:</b>	Antibiotic; Bacterial
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (197.41 mM; Need ultrasonic)  
DMSO : 50 mg/mL (98.70 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9741 mL	9.8705 mL	19.7410 mL
	5 mM	0.3948 mL	1.9741 mL	3.9482 mL
	10 mM	0.1974 mL	0.9870 mL	1.9741 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Mupirocin (BRL-4910A) lithium is an orally active antibiotic isolated from *Pseudomonas fluorescens*. Mupirocin lithium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis<sup>[1][2][3][4][5]</sup>.

### REFERENCES

- [1]. Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. *Antimicrob Agents Chemother.* 1985 Apr;27(4):495-8.
- [2]. Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. *Clin Pharm.* 1987 Oct;6(10):761-70.
- [3]. Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of methicillin-resistant *Staphylococcus aureus* in a murine superficial skin wound infection model. *Int J Antimicrob Agents.* 2013 Sep. 42(3):272-5.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA